Bone loss associated with prevention of breast cancer

The Lancet Oncology

Volumn 13, Issue 3, 2012, Pages 221-222

  Cauley, Jane A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; BONE REMODELING; BONE STRENGTH; BREAST CANCER; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; GYNECOLOGIC DISEASE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LETTER; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; THROMBOEMBOLISM; TRABECULAR BONE;

ANDROSTADIENES; ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; BONE AND BONES; BONE DENSITY; BREAST NEOPLASMS; FEMALE; HUMANS; OSTEOPOROSIS; POSTMENOPAUSE; PRIMARY PREVENTION;

EID: 84857506074     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70030-X     Document Type: Letter

References (11)

1. Gluck S, Gorouhi F Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer. Am J Health Syst Pharm 2011, 68:1699-1706.
2. Geisler J, Lonning PE Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol 2010, 118:294-299.
3. Gluck S Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. Am J Clin Oncol 2010, 33:314-319.
4. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004, 10:5717-5723.
5. Lonning PE Aromatase inhibitors in breast cancer. Endocr Relat Cancer 2004, 11:179-189.
6. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011, 364:2381-2391.
7. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA 1996, 276:1404-1408. Study of Osteoporotic Fractures Research Group.
8. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 2012, published online February 7. 10.1016/S1470-2045(11)70389-8.
9. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy.
10. Shi N, Foley K, Lenhart G, Badamgarav E Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 2009, 45:1084-1090.
11. Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.